Results 21 to 30 of about 25,619,860 (266)

CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach [PDF]

open access: yes, 2008
We retrospectively studied the single and combined diagnostic value of carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21-1), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP), which were routinely analysed in ...
Gruber, Christine   +4 more
core   +1 more source

Multifunctional role of PED/PEA15 in cell death and cell motility in human non small cell lung cancer (NSCLC) [PDF]

open access: yes, 2009
PED (phosphoprotein enriched in diabetes) is a 15 KDa protein involved in many cellular pathways and human diseases, including type II diabetes and cancer. We recently reported its overexpression in breast and lung cancers, and B-cell chronic lymphocytic
Zanca, Ciro
core   +1 more source

Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]

open access: yes, 2013
Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Hennen, Elisabeth   +24 more
core   +2 more sources

MYC is a metastasis gene for non-small-cell lung cancer. [PDF]

open access: yes, 2009
Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn   +25 more
core   +2 more sources

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

open access: yes, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Schmidt, Michael   +8 more
core   +1 more source

Prognostic significance of folate metabolism polymorphisms for lung cancer. [PDF]

open access: yes, 2007
Functional nonsynonymous single-nucleotide polymorphisms (nsSNPs) of folate metabolism genes can influence the methylation of tumour suppressor genes, thereby potentially impacting on tumour behaviour.
El Galta, R   +13 more
core   +1 more source

Immunotherapy of lung cancer: An update [PDF]

open access: yes, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A.   +15 more
core   +1 more source

Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer [PDF]

open access: yes, 2010
Lung cancer is the leading cause of cancer deaths, because ~84% of cases are diagnosed at an advanced stage. Worldwide in 2008, ~1.5 million people were diagnosed and ~1.3 million died – a survival rate unchanged since 1960.
Alex Stewart   +68 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy